Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
1. Madrigal secures a $500 million credit facility to enhance its MASH pipeline. 2. The deal includes a $350 million term loan and a $150 million delayed draw. 3. Madrigal aims to extend its leadership in MASH with non-dilutive funding. 4. The facility supports strategic business development and pipeline expansion. 5. Madrigal's Rezdiffra patent ensures protection through 2044, enhancing market position.